Sign in Subscribe
Pharmaceutical industry

Oncolytics Biotech Inc. Receives MHRA Approval for Phase II Clinical Trial of Reolysin Combination Therapy

Strategic Insights

— 1 min read

Oncolytics Biotech Inc. (ONC, ONCY) has taken a crucial step forward in the development of its Reolysin-based cancer therapy, with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granting approval for a Phase II clinical trial. The trial aims to evaluate the anti-tumor effects of intratumoral administration of Reolysin in combination with low-dose radiation in patients with advanced cancers. This marks a significant milestone for Oncolytics, a biotechnology company dedicated to developing innovative cancer treatments.

Key Takeaways:

  • The Phase II clinical trial will evaluate the combination of Reolysin with low-dose radiotherapy in patients with advanced cancers, including head and neck, esophageal, and other types of cancers.
  • The trial will enroll up to 40 evaluable patients, with approximately 20 patients with head and neck or esophageal cancers, and approximately 20 patients with other advanced cancers.
  • Patients will receive two intratumoral doses of Reolysin at 1x10^10 TCID^50, with a constant localized radiation dose of 20 Gy in five consecutive daily fractions.
  • The primary objective of the trial is to assess the antitumor activity of the combination of Reolysin and low-dose radiotherapy in treated and untreated lesions.
  • Secondary objectives include evaluating viral replication, immune response to the virus, and determining the safety and tolerability of intratumoral administration of Reolysin in patients with advanced cancers receiving radiation treatment.
  • Eligible patients include those with advanced or metastatic cancers, including head, neck, and esophageal tumors that are refractory to standard therapy or for which no curative standard therapy exists.

Statistics:

  • Up to 40 evaluable patients will be enrolled in the Phase II clinical trial.
  • Approximately 20 patients will have head and neck or esophageal cancers.
  • Approximately 20 patients will have other advanced cancers.
  • 1x10^10 TCID^50 is the dosage of Reolysin to be administered intratumorally.
  • 20 Gy is the constant localized radiation dose to be delivered in five consecutive daily fractions.

Sources:

  • Health & Medicine Week editors from staff and other reports.
  • 2006, Health & Medicine Week via NewsRx.com.

Read more